|
|
Article: Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway.
- Article from:
- PR Newswire
- Article date:
- August 22, 2007
CopyrightCOPYRIGHT 2007 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SEATTLE, Aug. 22 /PRNewswire-FirstCall/ -- Systems Medicine, LLC (SM), a wholly-owned subsidiary of Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC), today announced they have entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) of the National Institutes of Health (NIH). The goal of this CRADA is to develop patented products for the treatment of patients with cancer -- specifically, human monoclonal antibodies (hmAbs), peptides, and small molecules that affect signal transduction through the insulin-like growth factor (IGF) receptor type I (IGF-IR) and the insulin receptor (IR).
Under terms of the ...
Related newspaper, magazine, and journal articles:
|
|
Article: Cell Therapeutics, Inc. (CTI) to Sponsor Conference ...
PR Newswire;
October 17, 2007 ;
700+ words
... ... FirstCall/ -- Cell Therapeutics, Inc. (CTI ... update on lung cancer research, and the importance ... Scientific Director of Cell Therapeutics Europe S.r ... health. About Cell Therapeutics, Inc. Headquartered ...
|
|